<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03245021</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-676</org_study_id>
    <nct_id>NCT03245021</nct_id>
  </id_info>
  <brief_title>Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A</brief_title>
  <acronym>1stFLOR</acronym>
  <official_title>First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Eliza Hawkes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Austin Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Firstline treatment for grade 13a Follicular Lymphoma using Opdivo (nivolumab) plus&#xD;
      Rituximab: The 1st FLOR trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will involve participants with a condition called Follicular NonHodgkin Lymphoma&#xD;
      (Follicular Lymphoma).&#xD;
&#xD;
      The main purpose of this study is to see if it is safe to give drug Nivolumab before and in&#xD;
      combination with drug Rituximab and to see how effective Nivolumab is in patients who have&#xD;
      had no previous drug treatment for their lymphoma. In particular, we will be monitoring for&#xD;
      any specific side effects which may be increased by adding Nivolumab to Rituximab treatment,&#xD;
      including monitoring of the immune system.&#xD;
&#xD;
      Participants will be reviewed at baseline and prior to each cycle of treatment for toxicity,&#xD;
      scans will be performed at baseline, after 4 cycles of nivolumab, after 8 cycles of nivolumab&#xD;
      +/rituximab and at 6 months post induction treatment phase and following completion of&#xD;
      treatment, participants will be followed up for a total of 5 years (every 3 months for 2&#xD;
      years, every 6 months for 3 years). In participants with relapsed disease, these will be&#xD;
      followed for survival every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the feasibility and safety of combination nivolumab and rituximab as determined by the proportion of toxicity grade 3 or higher per CTCAE v4.0 occurring on induction treatment (ie first 16 weeks of therapy)</measure>
    <time_frame>1st 16 weeks of therapy</time_frame>
    <description>As determined by rate of toxicity grade 3 or higher per CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>As determined by rate of toxicity grade 3 or higher per CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>1st 16 weeks of therapy</time_frame>
    <description>Response Rate to Nivolumab + Rituximab according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>6 months post completion of induction treatment</time_frame>
    <description>Response Rate to Nivolumab + Rituximab according to the Lugano classification for Response Criteria for Non-Hodgkin Lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>5 years</time_frame>
    <description>Time to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Duration of survival without relapse or non-relapse mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall toxicity as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Opdivo - Single-arm open label study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opdivo</intervention_name>
    <description>All patients will receive:&#xD;
Nivolumab 240mg IV q2-weekly for four cycles&#xD;
Patients in complete remission (CR):&#xD;
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)&#xD;
Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:&#xD;
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles&#xD;
Patients in CR:&#xD;
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)&#xD;
Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:&#xD;
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles</description>
    <arm_group_label>Open-Label</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Histologically proven Follicular non Hodgkin lymphoma (FL) grades 1-3A according to&#xD;
             the current World Health Organization classification.29 The B cell nature of the&#xD;
             proliferation must be verified by the positivity with an anti-CD20 antibody.&#xD;
&#xD;
          3. No previous chemotherapy, or other investigational drug for this indication apart from&#xD;
             focal radiotherapy.&#xD;
&#xD;
          4. Stage II-IV disease (Ann Arbor criteria). Stage II disease must not be encompassable&#xD;
             in a single radiotherapy field and being considered for definitive radiotherapy.&#xD;
&#xD;
          5. Eastern Collaborative Oncology Group (ECOG) performance status 0 to 1 unless&#xD;
             attributable to lymphoma, in which case patients of performance status 2 are also&#xD;
             eligible.&#xD;
&#xD;
          6. Deemed to need treatment by treating investigator. Reasons for treatment can include,&#xD;
             but are not limited to:&#xD;
&#xD;
        a. Any nodal or extranodal tumour mass &gt;7cm AND/OR multiple extranodal disease sites b.&#xD;
        Involvement of at least 3 sites each with diameter &gt;3cm c. Symptomatic splenic enlargement&#xD;
        d. Organ involvement/compression e. Ascites or pleural effusion f. Lactate Dehydrogenase&#xD;
        (LDH) elevated g. Presence of systemic symptoms h. Disease progression in preceding 3&#xD;
        months i. Evidence of marrow infiltration with marrow compromise. (eg Hb, WBC or plt count&#xD;
        below lower limit of institutional normal range).&#xD;
&#xD;
        g) Adequate bone marrow function including:&#xD;
&#xD;
          1. Haemoglobin &gt;9.0 g/dL&#xD;
&#xD;
          2. White blood cells (WBC) ≥2000/μL&#xD;
&#xD;
          3. Neutrophils &gt;1.5 x 109/L&#xD;
&#xD;
          4. Platelets &gt;100 x 109/L at the time of study entry, unless attributed to bone marrow&#xD;
             infiltration by lymphoma.&#xD;
&#xD;
        h) Adequate renal function with serum creatinine ≤1.5 x ULN or creatinine clearance (CrCl)&#xD;
        ≥ 40mL/min (using Cockroft-Gault formula) Female CrCl = (140 - age in years) x weight (kg)&#xD;
        x 0.85 72 x serum creatinine (mg/dL) Male CrCl = (140 - age in years) x weight (kg) x 1.00&#xD;
        72 x serum creatinine (mg/dL) i) Adequate hepatic function with AST/ALT ≤3x ULN and total&#xD;
        bilirubin ≤1.5 x ULN (except subjects with Gilbert syndrome, who can have a total bilirubin&#xD;
        ≤3 mg/dL or ≤51.3 μmol/L) j) Life expectancy &gt; 3 months. k) Patients of childbearing&#xD;
        potential willing to adhere to contraceptive precautions&#xD;
&#xD;
          1. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to&#xD;
             the start of study treatment&#xD;
&#xD;
          2. Women must not be breastfeeding&#xD;
&#xD;
          3. WOCBP must use appropriate method(s) of contraception to avoid pregnancy for 23 weeks&#xD;
             (30 days plus five half-lives of nivolumab) post-treatment completion&#xD;
&#xD;
          4. Men who are sexually active with WOCBP must use any contraceptive method with a&#xD;
             failure rate of less than 1% per year. They must agree to adhere to contraception for&#xD;
             a period of 31 weeks after the last day of nivolumab.&#xD;
&#xD;
          5. Azoospermic males and WOCBP who are continuously not heterosexually active are exempt&#xD;
             from contraceptive requirements. However, they must still undergo pregnancy testing as&#xD;
             described in this section.&#xD;
&#xD;
        l) Written, informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Grade 3B follicular lymphoma, transformed follicular lymphoma, other indolent&#xD;
             lymphomas.&#xD;
&#xD;
          2. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4&#xD;
             antibody or any other antibody or drug specifically targeting T-cell co-stimulation or&#xD;
             checkpoint pathways.&#xD;
&#xD;
          3. Central nervous system, meningeal involvement or cord compression by lymphoma.&#xD;
&#xD;
          4. Patients with active, known or suspected autoimmune disease. Patients with well&#xD;
             controlled type I diabetes mellitus, coeliac disease, residual hypothyroidism due to&#xD;
             autoimmune condition only requiring hormone replacement, vitiligo or psoriasis not&#xD;
             requiring systemic treatment, or other conditions not expected to recur in the absence&#xD;
             of an external trigger are permitted to enrol.&#xD;
&#xD;
          5. Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10mg daily prednisone equivalents) or other immunosuppressive medications within 14&#xD;
             days of study drug administration. Inhaled or topical steroids, and adrenal&#xD;
             replacement doses &gt; 10 mg daily prednisone equivalents are permitted in the absence of&#xD;
             active autoimmune disease.&#xD;
&#xD;
          6. Past history of interstitial lung disease.&#xD;
&#xD;
          7. Prior malignancy active within the previous 3 years except for locally curable cancers&#xD;
             that have been apparently cured, such as basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.&#xD;
&#xD;
          8. Any other serious active disease.&#xD;
&#xD;
          9. Any positive test result for hepatitis B or hepatitis C virus during screening&#xD;
             indicating acute or chronic infection.&#xD;
&#xD;
         10. Any positive test for human immunodeficiency virus (HIV) or known acquired&#xD;
             immunodeficiency syndrome (AIDS)&#xD;
&#xD;
         11. Any history of severe hypersensitivity reactions to other monoclonal antibodies. A&#xD;
             history of allergy or intolerance (unacceptable AEs) to study drug components or&#xD;
             Polysorbate-80-containing infusions&#xD;
&#xD;
         12. Medical or psychiatric conditions that compromise the patient's ability to give&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliza Hawkes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Austin Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eliza Hawkes, MD</last_name>
    <phone>+61 3 9496 5763</phone>
    <phone_ext>5763</phone_ext>
    <email>eliza.hawkes@onjcri.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Marie Woods, BSc</last_name>
    <phone>+61 3 9496 3352</phone>
    <phone_ext>3352</phone_ext>
    <email>Anne-Marie.WOODS@austin.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ballarat Health</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Su-Ann Hampson, Bsc</last_name>
      <phone>+61 3 5320 6459</phone>
      <phone_ext>6459</phone_ext>
      <email>su-annh@bhs.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicity McLeary, Bsc</last_name>
      <phone>+61 3 9095 2465</phone>
      <phone_ext>2465</phone_ext>
      <email>felicity.mcleary@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Spence, Bsc</last_name>
      <phone>+61 3 95944044</phone>
      <phone_ext>4044</phone_ext>
      <email>laura.spence@monashhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Houdyk, BSc</last_name>
      <phone>+61 3 9496 9919</phone>
      <phone_ext>9919</phone_ext>
      <email>kristen.houdyk@austin.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Caihoang, Bsc</last_name>
      <phone>+61 3 9231 3117</phone>
      <phone_ext>3117</phone_ext>
      <email>andrew.caihoang@svha.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 7, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2017</study_first_posted>
  <last_update_submitted>January 13, 2019</last_update_submitted>
  <last_update_submitted_qc>January 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Austin Health</investigator_affiliation>
    <investigator_full_name>Dr. Eliza Hawkes</investigator_full_name>
    <investigator_title>Chief Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>IPD is the property of the Sponsor (Austin Health). Results from the research intends to be published/presented in relevant publications/conferences for colleague review</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

